Search hospitals
>
Montana
>
Bozeman
Bozeman Deaconess Hospital
Claim this profile
Bozeman, Montana 59715
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
402 reported clinical trials
2 medical researchers
Summary
Bozeman Deaconess Hospital is a medical facility located in Bozeman, Montana. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Bozeman Deaconess Hospital is involved with conducting 402 clinical trials across 476 conditions. There are 2 research doctors associated with this hospital, such as John M. Schallenkamp and Benjamin T. Marchello.
Area of expertise
Breast Cancer
Bozeman Deaconess Hospital has run 72 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Bozeman Deaconess Hospital has run 70 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
John M. Schallenkamp
Billings Clinic Cancer Center
7 years of reported clinical research
Benjamin T. Marchello
Kalispell Regional Medical Center
10 years of reported clinical research
Clinical Trials running at Bozeman Deaconess Hospital
Lung Cancer
Bladder Cancer
Breast Cancer
Prostate Cancer
Breast cancer
Ovarian Cancer
Cancer
Esophageal cancer
Kidney Cancer
Bladder Carcinoma
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting
2 awards
Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Bozeman Deaconess Hospital?
Bozeman Deaconess Hospital is a medical facility located in Bozeman, Montana. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Bozeman Deaconess Hospital is involved with conducting 402 clinical trials across 476 conditions. There are 2 research doctors associated with this hospital, such as John M. Schallenkamp and Benjamin T. Marchello.
Where is Bozeman Deaconess Hospital located?
**Bozeman Deaconess Hospital Location:** To reach Bozeman Deaconess Hospital, exit I-90 at North 19th Avenue and proceed north. Turn right onto Highland Blvd. The hospital's address is 915 Highland Blvd, Bozeman, MT 59715.
Who should I call to ask about financial aid or insurance network?
Bozeman Deaconess Hospital offers financial assistance and insurance support. For financial assistance, contact the Bozeman Health collection department at 406-414-1015 or mail completed applications to Bozeman Health, Attn: Patient Financial Services, 1600 Ellis St. 3rd Floor, Bozeman, MT 59715. Patients should direct insurance-related inquiries to their providers using the number on their insurance cards; Bozeman Health submits claims, but patients are liable for charges not covered by insurance.
What insurance does Bozeman Deaconess Hospital accept?
Bozeman Health Deaconess Hospital accepts a variety of insurance plans, including Allegiance, Blue Cross Blue Shield, Interwest Health, Medicare, Managed Medicare, Montana Medicaid, Montana United School Trust, New West, United Healthcare, and Work Compensation. The Deaconess Clinic, part of Bozeman Health, also accepts plans from Aetna, Allegiance/Cigna, Blue Cross/Blue Shield, EBMS, Pacific Source, United Healthcare, and Mountain Health Co-op. It is recommended to contact the hospital or clinic directly to confirm coverage for your specific insurance plan.
What awards or recognition has Bozeman Deaconess Hospital received?
Bozeman Deaconess Hospital is renowned for its clinical research, leading to FDA approval of new patient treatments. It also played a pivotal role during the COVID-19 pandemic by collaborating with local universities and suppliers to overcome testing challenges, showcasing its dedication to patient care and community support.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.